AptarGroup Reports Q3 2026 Sales Growth Amidst Margin Compression and Russian Deconsolidation
AptarGroup (ATR) reported third-quarter sales of $1.02 billion, a 6% increase driven by broad demand across its Beauty, Closures, and Pharma segments. Despite the revenue growth, adjusted earnings per share fell 6% to $1.52 due to higher interest expenses, an increased effective tax rate, and margin dilution caused by a shift in product mix. The company faced significant headwinds including a $61.2 million pre-tax loss from the deconsolidation of its Russian subsidiary and lower high-margin emergency medicine sales. While segments like Closures (11% growth) and Injectables (9% growth) showed strength, management noted operational challenges in North American Beauty operations and uncertainty regarding future naloxone demand trajectories.
Tickers: $ATR
Topics: Adjusted EPS EBITDA Margin Revenue Growth Segment Performance
Read the full article at Motley Fool
Part of the story AptarGroup Reports Q3 2026 Sales Growth Amidst Margin Compression and Russian Deconsolidation (3 articles)